



Q1 2026 Earnings Presentation

April 29, 2026

Forward-Looking Statements

This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025 and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Management has disclosed adjusted financial measurements in this presentation that present financial information that is not in accordance with generally accepted accounting principles in the United States (GAAP). The Company analyzes net sales on a constant currency basis and organic constant currency basis to better measure the comparability of results between periods. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. These measurements are not a substitute for GAAP measurements. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share, including its components, as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated statements of income.

CONMED Vision

Empower healthcare providers worldwide to deliver exceptional outcomes for patients.

Focus behind the Vision
People, Products, Profitability



WE DO
things the
right way.




WE MAKE
and keep
commitments.



WE OPERATE
with urgency.




WE BELIEVE
in the power of
engaged talent.



WE DELIVER
exceptional results.

Financial Performance Q1 2026



<p>Revenue</p> <p>\$317.0M</p> <p>-1.3% vs. Q1 2025 as reported -2.9% vs. Q1 2025 constant currency 2.1% vs. Q1 2025 organic constant currency</p>	<p>Diluted EPS</p> <p>\$0.45</p> <p>136.8% vs. Q1 2025</p>	<p>Adjusted Diluted EPS²</p> <p>\$0.89</p> <p>-6.3% vs. Q1 2025</p>
--	--	--

¹Growth rates shown versus the three months ended March 31, 2025 in constant currency. The reconciliation to GAAP numbers is included in our earnings release issued on April 29, 2026.
²Adjusted diluted EPS excludes the costs of special items, including charges for operational optimization costs, executive transition costs, EU medical device regulations (MDR), contingent consideration, termination of distribution agreement, gain on sale of product line, legal matters, and amortization of intangible assets and deferred financing fees, net of tax.
³See appendix for organic growth rate reconciliation.



2026 Financial Guidance Update

Revenue & Adjusted EPS

Revenue

	1 st Quarter Actual	2 nd Quarter Guide	2 nd Half Guide	Updated 2026 Guide	Previous 2026 Guide
Organic Constant Currency	\$302.5M 2.1% growth	\$334M to \$335.3M 5.4% to 5.8% growth	\$694.7M to \$712.3M 6.2% to 8.9% growth	\$1,331.2M to \$1,350.1M 5% to 6.5% growth	\$1,324M to \$1,344M ~4.5% to ~6% growth
<i>Estimated G.I. Revenue¹</i>	\$9.5M	\$2M to \$3M	\$3M to \$5M	\$14.5M to \$17.5M	\$21M to \$25M
<i>Estimated Foreign Currency Impact</i>	\$5.0M 160 BP tailwind	\$0M to \$1.7M 0 to 50 BP tailwind	\$(0.7)M to \$0.7M 20 BP headwind to 20 BP tailwind	\$4.3M to \$7.4M 40 to 50 BP tailwind	\$0M to \$6M 0 to 50 BP tailwind
Total Reported Revenue	\$317M	\$336M to \$340M	\$697M to \$718M	\$1,350M to \$1,375M	\$1,345M to \$1,375M

Adjusted EPS

	2026 Guide
Total Adjusted EPS	\$4.30 to \$4.45 <i>No change (includes updated impact of 2026 debt refinancing)</i>

¹The decrease in estimated G.I. revenue is due to the Company's earlier-than-anticipated divestiture of its G.I. products.

CONMED Driven to Win

➤ **Leveraging Growth Drivers**

Focusing on high-growth, high-margin products: AirSeal, Buffalo Filter, BioBrace

➤ **Optimizing Portfolio**

Exiting gastroenterology to align resources with minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair

➤ **Transforming Supply Chain**

Driving supply chain transformation focused on resiliency, predictability, scalability, and efficiency

➤ **Strengthening Balance Sheet**

Enhancing balance sheet to drive growth and shareholder returns

Environmental, Social and Governance

Together we are making a difference for a better tomorrow

View CONMED's full 2024 ESG Report on [CONMED.com](https://www.conmed.com)

Environmental



CONMED manufacturing operations have recycling programs including eScrap, metal, cardboard, plastic, and paper.



Use of ISO 14001 and 45001 as a framework to harmonize an Environmental Management System across CONMED.



Development of capabilities to measure and understand greenhouse gas emissions associated with our operations, and to identify areas of high impact and opportunities for reduction.

Social



Partners with the United Way to serve communities where we operate in the U.S.



98% of employees participated in the Gallup Q12 Employee Engagement Survey.



Committed to maintaining a quality system that provides safe and effective products and services that meet the needs and requirements of our patients, customers, company stakeholders and all regulatory requirements.

Governance



In addition to oversight by the full Board, the ESG Steering Committee provides strategic direction and prioritization of ESG initiatives.



CONMED's executive leadership is responsible for setting the ethical code and overseeing compliance.



Effective board leadership and independent oversight. 100% independent standing board committees and regular executive sessions of independent directors.

Appendix

Organic¹ (ex. GI) Revenue Reconciliation

Sales Summary (in millions, unaudited)

Three Months Ended March 31,

			% Change										
							Domestic			International			
	2026	2025	As Reported	Impact of GI	Impact of Foreign Currency	Organic ¹ Constant Currency	As Reported	Impact of GI ⁽¹⁾	Organic ¹	As Reported	Impact of GI	Impact of Foreign Currency	Organic ¹ Constant Currency
Orthopedic Surgery	\$ 147.7	\$ 138.3	6.8%	0.0%	-2.3%	4.5%	5.5%	0.0%	5.5%	7.6%	0.0%	-3.7%	3.9%
General Surgery	169.3	183.0	-7.4%	8.6%	-1.1%	0.0%	-10.4%	11.9%	1.5%	0.1%	0.6%	-3.9%	-3.3%
	<u>\$ 317.0</u>	<u>\$ 321.3</u>	<u>-1.3%</u>	<u>5.1%</u>	<u>-1.6%</u>	<u>2.1%</u>	<u>-5.8%</u>	<u>8.6%</u>	<u>2.8%</u>	<u>4.7%</u>	<u>0.3%</u>	<u>-3.7%</u>	<u>1.3%</u>
Domestic	\$ 173.0	\$ 183.8	-5.8%	8.6%	0.0%	2.8%							
International	144.0	137.5	4.7%	0.3%	-3.7%	1.3%							
	<u>\$ 317.0</u>	<u>\$ 321.3</u>	<u>-1.3%</u>	<u>5.1%</u>	<u>-1.6%</u>	<u>2.1%</u>							

¹Organic growth rates exclude gastroenterology sales from 2025 and 2026